MMAF sodium is primarily used in the development of antibody-drug conjugates (ADCs), which are targeted cancer therapies. It functions as a potent cytotoxic agent, designed to kill cancer cells selectively. When conjugated to a monoclonal antibody, MMAF sodium is delivered directly to cancer cells, minimizing damage to healthy tissues. Its mechanism of action involves inhibiting cell division by disrupting microtubule function, leading to apoptosis. This makes it a valuable component in precision medicine for treating various cancers, including hematologic malignancies and solid tumors. Research continues to explore its efficacy and potential in combination with other therapeutic strategies.